Oncotarget

Research Papers:

Small flexible structure for targeted delivery of therapeutic and imaging moieties in precision medicine

Shaofan Hu, Wei Wang, Yanling Zhang, Bingjie Li, Xiuchun Qiu, Chaoxia Zou, Henry Ran, Fujun Zhang _ and Shi Ke

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:25535-25548. https://doi.org/10.18632/oncotarget.8335

Metrics: PDF 1368 views  |   HTML 1676 views  |   ?  


Abstract

Shaofan Hu1,2*, Wei Wang3,*, Yanling Zhang4,5,*, Bingjie Li1, Xiuchun Qiu3,6, Chaoxia Zou3,7, Henry Ran3, Fujun Zhang3,5, Shi Ke1,3

1UTHealth, School of Public Health, Houston, Texas, USA

2Jiangxi Children's Hospital, Nanchang, China

3Baylor College of Medicine, Houston, Texas, USA

4School of Biotechnology, Southern Medical University, Guangzhou, China

5Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

6The Fourth Military Medical University, Xi’an, China

7Harbin Medical University, Harbin, China

*These authors contributed equally to this work

Correspondence to:

Fujun Zhang, e-mail: [email protected]

Shi Ke, e-mail: [email protected], [email protected]

Keywords: precision medicine, target-specific imaging, target-specific therapy, molecule imaging, molecule therapy

Received: February 02, 2016     Accepted: March 10, 2016     Published: March 24, 2016

ABSTRACT

The goals of precision medicine are to link diagnostic and therapeutic agents, improve clinical outcomes, and minimize side effects. We present a simple, small, flexible three-armed core structure that can be conjugated to targeting, imaging, and therapeutic moieties. The targeting molecule can be a peptide, protein, or chemical compound. The diagnostic reporter can be optical and/or nuclear in nature, and can be replaced by chemo- and/or radiotherapeutic compounds for treatment using a single targeting molecule. Imaging components can be used to detect disease biomarkers, monitor treatment response, and guide surgery in real-time to create a tumor-free margin. Isotope impurity can be exploited to visualize whole-body distribution of therapeutic agents. The one-to-one ratio of targeting component to therapeutic agents facilitates dose calculation. The simple synthesis and flexible, modular nature of the agent facilitate high-purity, large-scale production. The core capacity to “seek, treat, and see” may advance precision medicine in the future.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8335